Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01174290 · ClinicalTrials.gov registry record · Phase 4
Preventing ICU Subsyndromal Delirium Conversion to Delirium With Haloperidol
A Phase 4 study, sponsored by Northeastern University.
- Completed
- Registry status
- Phase 4
- Development phase
- 68
- Enrollment target
NCT01174290 is a Phase 4 study that has completed, run by Northeastern University. The registered enrollment target is 68 participants.
The verdict
NCT01174290, a Phase 4 study, has completed, sponsored by Northeastern University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 68 participants
- Enrollment target
Study Summary
About one-third of the patients who develop mild, acute confusion (i.e., subsyndromal delirium) will go on to develop a severe acute confusional state (i.e. delirium). Delirium refers to a temporary change in the way a person thinks about things. Delirium occurs in patients admitted to the hospital particularly those patients that are very sick, who are given a number of medications, and who are not able to sleep normally. It affects their behavior, their understanding of the people and things around them, and their ability to make decisions. While ICU doctors do everything possible to eliminate the factors that may cause delirium, delirium may cause a person to become very agitated which if not controlled is dangerous to their safety as well as the safety of those around them. As well, if delirium develops in patients in the ICU, it may increase the risk for death, keep patients in both the ICU and hospital for longer and send patients to a long term care facility rather than home after they are discharged from the hospital. A recent medical report found that patients in the ICU who develop subsyndromal delirium have a mortality rate, a length of stay in both the ICU and the hospital, and a transfer rate to a long term care facility that is nearly as great as patients with delirium and greater than patients who develop neither subsyndromal delirium or delirium. Recent studies in non-ICU patients suggest that if a patient who is at high risk for developing delirium receives a medication called an antipsychotic (e.g. haloperidol) they may not be as likely to develop delirium or if they do develop delirium it will not last as long. No studies have evaluated the effect of administering an antipsychotic in patients in the ICU who have subsyndromal delirium. Another study completed in the ICUs at Tufts Medical Center found that there may be an association between the development of delirium in patients with subsyndromal delirium and the use of haloperidol. However, this
Interventions
- DRUG Placebo
- DRUG Haloperidol decanoate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2010-09 |
| Est. Completion | 2014-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01174290
The ClinicalTrials.gov registry entry for NCT01174290 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northeastern University, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01174290 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01174290 about?
NCT01174290 is a clinical study titled "Preventing ICU Subsyndromal Delirium Conversion to Delirium With Haloperidol". About one-third of the patients who develop mild, acute confusion (i.e., subsyndromal delirium) will go on to develop a severe acute confusional state (i.e. delirium). Delirium refers to a temporary change in the way a person thinks about things. Delirium occurs in patients admitted to the hospital ...
What is the current status of trial NCT01174290?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 68 participants. The study started on 2010-09. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01174290?
The interventions under investigation include: Placebo (DRUG), Haloperidol decanoate (DRUG).
Who is sponsoring clinical trial NCT01174290?
This trial is sponsored by Northeastern University, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.